Form 4: Cartesian Therapeutics Officer Milos Miljkovic Reports Changes in Beneficial Ownership Following Reverse Stock Split and Preferred Stock Conversion
SEC Form 4
Milos Miljkovic, Chief Medical Officer of Cartesian Therapeutics, reports adjustments to his stock options and common stock holdings following a reverse stock split and the conversion of Series A Preferred Stock.
Summary
- Milos Miljkovic, the Chief Medical Officer of Cartesian Therapeutics, filed a Form 4 detailing changes in his beneficial ownership of company stock.
- These changes are due to a 1-for-30 reverse stock split that Cartesian Therapeutics implemented on April 4, 2024.
- Additionally, the conversion of Series A Non-Voting Convertible Preferred Stock into common stock occurred on April 8, 2024, impacting Miljkovic's holdings.
- The filing details adjustments to stock options, including those originally related to Old Cartesian common stock that were converted into options for Series A Preferred Stock following the acquisition of Old Cartesian on November 13, 2023.
- Some options are now exercisable for common stock, with the remaining portions vesting in the future.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing changes in stock ownership due to corporate actions. It doesn't inherently convey positive or negative sentiment.
Future Outlook
Some stock options vest in the future, with full vesting occurring on January 2, 2028, for one set of options, and on September 13, 2024 and 2025 for another set of options.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track changes in ownership and potential alignment of interests.
Stakeholder Impact
- Shareholders are informed about changes in insider ownership, which can influence investor confidence.
Key Dates
| Date | Description |
|---|---|
| November 13, 2023 | Cartesian Therapeutics acquired Old Cartesian. |
| March 27, 2024 | Special meeting of stockholders approved the reverse stock split and conversion of Series A Preferred Stock. |
| April 4, 2024 | Cartesian Therapeutics effected a 1-for-30 reverse stock split. |
| April 8, 2024 | Conversion of Series A Non-Voting Convertible Preferred Stock into common stock occurred. |
| April 8, 2024 | Earliest transaction date reported on the Form 4. |
| April 10, 2024 | Date of Form 4 filing. |
| September 12, 2031 | Expiration date for some stock options. |
| January 1, 2034 | Expiration date for some stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.